Gland Pharma Ltd Share Price Today - Gland Pharma Ltd Stock Price Live NSE/BSE

Gland Pharma Ltd

NSE: GLAND BSE: 543245

₹1780.80

(-1.94%)

Sat, 14 Feb 2026, 03:41 am

MTF 5xInvest in Gland Pharma Ltd with 5x Leverage Buy with MTF

Market Cap299.08B

PE Ratio34.63

Dividend0.99

Health Technology

Pharmaceuticals: Major

24.5K

Gland Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
29320.88
Net Profit
698.53
P/B
2.87
Sector P/E
32.04
P/E
37.55
EV/EBITDA
16.18
Debt/Equity (Industry)
0.24
Interest Cover (Industry)
12.78
ROCE (Industry)
15.36
RONW (Industry)
13.46
ROE
7.82
ROCE
11.67
Debt/Equity
0.04
EPS (TTM)
52.45
Dividend Yield
1.01
Book Value
580.41
Interest Cover
26.30

Analysis

No Result Found

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	51.83	51.83	51.83	51.83	51.83
FII	7.58	7.91	7.39	6.90	5.04
DII	32.98	32.64	32.85	33.27	34.80
Public	7.61	7.63	7.93	7.99	8.33
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

47.99

MACD

32.81

50 DMA

1734.47

200 DMA

1803.29

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	2240.07	2015.27	1930.93	1790.47	1706.13	1565.67	1340.87
Fibonacci	2015.27	1929.39	1876.34	1790.47	1704.59	1651.54	1565.67
Camarilla	1908.42	1887.81	1867.21	1790.47	1825.99	1805.39	1784.78

Pivots Level: Classic

+449.60

2240.07

+224.80

2015.27

+140.47

1930.93

1790.47

Pivot Point

LTP: 1780.80

-84.33

1706.13

-224.80

1565.67

-449.60

1340.87

Moving Average

SMAEMA

Period

Value

10-EMA
1833.03
20-EMA
1808.53
30-EMA
1790.27
50-EMA
1780.36
100-EMA
1790.72
200-EMA
1787.37

Announcement Date	Purpose	Action	Ex Date
28 Jan 2026	board-meetings	Quarterly Results
03 Nov 2025	board-meetings	Quarterly Results
20 May 2025	dividend	₹18.00 Dividend /Share	14 Aug 2025
20 May 2025	agm
22 May 2024	agm
22 May 2024	dividend	₹20.00 Dividend /Share	16 Aug 2024
18 May 2023	agm
19 May 2022	agm
17 May 2021	agm

Gland Pharma Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Cipla Ltd

Gland Pharma Ltd About

Gland Pharma is primarily engaged in manufacturing injectable formulations. The Company’s shares are listed on BSE Limited and National Stock Exchange of India Limited.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1978

Headquarters

CEO

SRINIVAS SADU

Employees

Contact

Website

http://www.glandpharma.com

investors@glandpharma.com

Phone

91-40-30510999

Location

Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043

Year	History
2019	The company filed Dexrazoxane for Injection, its first filing with the National Medical Products Administration, China, and received clinical waiver
2020	Gland Pharma along with its partners MAIA Pharmaceuticals, Inc. and Athenex Pharmaceutical Division announce the launch of a Ready-to-Use Bivalirudin Injection in the United States of America
2021	Gland Pharma received approval for generic Foscarnet Sodium Injection, Single-Dose Bag for Infusion Gland Pharma receives Tentative Approval for Sugammadex Injection Gland Pharma receives tentative approval for Cangrelor injection
2022	Gland Pharma enters into put option agreement to acquire 100% of Cenexi Group Gland Pharma announces launch of Bortezomib for Injection in US market
2024	The Company received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection

Client Name	Order Side	QTY	Avg Price	Date
VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VIEIF	Buy	838556	1588.69	21 Mar 2025
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Buy	1016219	1588.69	21 Mar 2025
FOSUN PHARMA INDUSTRIAL PTE. LTD.	Sell	9900000	1771.81	19 Jun 2024
UBS PRINCIPAL CAPITAL ASIA LIMITED	Buy	825000	1771.05	19 Jun 2024
NICOMAC MACHINERY PRIVATE LIMITED	Sell	1955452	1735.31	09 Apr 2024
LAKUMI TRUST	Sell	6165486	1739.1	09 Apr 2024

Gland Pharma Ltd News

Gland Pharma Gets USFDA Nod for Zoledronic Acid

Gland Pharma receives USFDA approval for Zoledronic Acid injection targeting hypercalcemia of malignancy and multiple myeloma. US sales projected at USD 6.7 million by November 2025.

06 Feb 2026

stocks

Gland Pharma COO Satnam Singh Loomba to Retire

Gland Pharma announces retirement of Chief Operating Officer Mr. Satnam Singh Loomba effective March 31, 2026, due to superannuation after serving since May 2024.

29 Jan 2026

stocks

Gland Pharma Q3 FY26: 22% Revenue Growth, Strong Margins

Gland Pharma reported strong Q3 FY26 results with consolidated revenue of ₹16,953.63 million (22% YoY growth) and adjusted PAT of ₹2,797 million (37% YoY growth). The company also reappointed Grant Thornton as internal auditors.

28 Jan 2026

co actions results

Gland Pharma Exports Surge 62% Month-on-Month

Gland Pharma reports significant 62% month-on-month growth in exports, demonstrating strong international market performance and operational momentum in pharmaceutical business.

13 Jan 2026

stocks

Gland Pharma Board Meet Set for Jan 28 Q3 Results

Gland Pharma Limited announces board meeting on January 28, 2026 to approve Q3FY26 unaudited financial results for quarter ended December 31, 2025. Trading window reopens January 31.

09 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800

Gland Pharma Ltd

Gland Pharma Share Price Live Chart

Summary

Analysis

Financials

Ratios

Shareholding

Technical Analysis

Corporate Actions

Peer Comparison

Gland Pharma Ltd About

Contact

Gland Pharma Ltd Company History

Deals

Gland Pharma Ltd News